Two comments which won't be popular but I think are fair:
The study only had 3 patients
The figures in the table are not particularly overwhelming
I am a long-only investor but I think it's beneficial to follow companies with high short positions to see if the institutional money calls it correctly (they nearly always do: short squeezes are a generally a retail investor mirage). My guess is that with PNV sitting at #9 on the most shorted list, those who are short will probably take this move as an opportunity to increase their positions, because this announcement changes nothing about the fundamental reasons they are short the stock (an anticipated funding gap due to the cash burn). I would not be surprised if shorters look at an announcement that segues from a 3-person trial to a US$34B market opportunity and thinks: "retail pump".
PNV Price at posting:
$1.67 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)